SPL 2.13% 9.6¢ starpharma holdings limited

The Chairman Rob Thomas in the 2017 annual report stated "In...

  1. 357 Posts.
    lightbulb Created with Sketch. 31


    The Chairman Rob Thomas in the 2017 annual report stated "In terms of the year ahead, Starpharma is on the cusp of several near term catalysts: commercialisation of its VivaGel® BV products; commencement and progress of clinical trials for multiple DEP® candidates; and more DEP®partnerships.


    Since we were on the cusp of more DEP partnerships in Aug 2017 and more than 12 months has passed. 

    Have I missed information on any DEP partnerships being signed since Aug 2017? Surely he was not talking about Vivagel partnerships.



 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.